

Amendments to the Claims:

Claims 1-20 (Canceled).

21. (Previously presented): Attenuated live parasite of the phylum Apicomplexa or the family of Trypanosomatidae, wherein said parasite comprises a ribosomal protein gene under the control of an inducible promoter.
22. (Previously presented): The attenuated live parasite according to Claim 21, wherein said parasite belongs to the Coccidia, the Piroplasmida or the Haemosporida.
23. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Eimeridiidae, Cryptosporidiidae or Sarcocystidae.
24. (Previously presented): The attenuated live parasite according to Claim 23, wherein said parasite belongs to the genus Eimeria, Cryptosporidium, Toxoplasma, Sarcocystis or Neospora.
25. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Babesiidae or the Theileriidae.
26. (Previously presented): The attenuated live parasite according to Claim 25, wherein said parasite belongs to the genus Babesia or Theileria.

27. (Previously presented): The attenuated live parasite according to Claim 22, wherein said parasite belongs to the genus Plasmodium.

28. (Previously presented): The attenuated live parasite according to Claim 21, wherein said parasite belongs to the genus Trypanosoma or the genus Leishmania

29. (Previously presented): The attenuated live parasite according to Claim 21, wherein said inducible promoter is based upon an operator site and a repressor protein capable of reversibly binding said operator site.

30. (Previously presented): The attenuated live parasite according to Claim 21, wherein said inducible promoter is inducible by antibiotics.

31. (Previously presented): The attenuated live parasite according to claim 20, wherein said inducible promoter is inducible by tetracycline or anhydrotetracyclin, or a derivative thereof.

32. (Previously presented): The attenuated live parasite according to claim 21, wherein a tetR-system is used as the inducible promoter.

33. (Currently amended): The attenuated live parasite according to **Claim 1, Claim 21,**

USSN: 10/526,731
Attorney Docket: 2002.017 US
Response to Office Action of October 31, 2007

wherein said ribosomal protein gene is the gene encoding L9, S3, plastid-S9 or S13, preferably L9, S3, plastid-S9 or S13 of *Toxoplasma gondii*.

34. (Currently amended): A vaccine for combating parasitic infection An immunogenic composition comprising the attenuated live parasite of Claim 21 and a pharmaceutically acceptable carrier.

35. (Currently amended): A method for the production of the vaccine according to Claim 34, an immunogenic composition, said method comprising the mixing of [[a]] the live attenuated parasite according to Claims-1 Claim 21 and a pharmaceutically acceptable carrier.

Claims 36-38 (Canceled).